Team-based AE protocols improve consistency with the gemcitabine intravesical therapy system

Distinguishing a manageable local adverse event from one that warrants intervention requires assessing both the proportionality and trajectory of a patient's symptoms—not a fixed threshold—and most patients experiencing irritative symptoms with the gemcitabine intravesical system (Inlexzo) can be supported through dose interruption rather than discontinuation, according to Elizabeth Mobley, MD.

Mobley, a urologist and president of Urology Austin in Texas, described her decision framework as grounded in a few key questions: Is the symptom a known local reaction that is stable or improving with supportive care? Is it escalating? Are there systemic symptoms? Approximately 41% of patients in the clinical trial required dose interruptions—most commonly for urinary tract infections, urinary tract pain, hematuria, urgency, dysuria, genital pain, and pelvic pain. Mobley framed interruptions for these reasons as expected and appropriate rather than concerning.

"We can skip doses, interrupt for a short period of time, let those patients recover and get back to their normal bladder symptoms, and then reestablish therapy," she said. "That's not a loss—we're still doing the right thing for the patient."

Permanent discontinuation is substantially rarer, occurring in approximately 7% of trial patients. In Mobley's experience, those cases typically involve patients with severely compromised baseline bladder function—contracted bladders, prior heavy disease burden, or significant prior resections—who are unlikely to tolerate any intravesical therapy well.

Mobley described one patient in detail: a man with extensive prior disease who developed dystrophic calcifications at resection sites requiring surgical removal—a complication she has also seen, albeit rarely, with liquid gemcitabine, mitomycin, and BCG. The resulting mucosal trauma and re-treatment cycle ultimately left the bladder unable to tolerate resumed therapy. Systemic consequences—elevated blood pressure, pain, sleep disruption, rising blood sugar—eventually drove the discontinuation decision.

"We had to weigh resuming therapy vs potentially putting him back on this and having all these other metabolic issues arise," Mobley said. The patient ultimately recovered better than expected without the device.

"He's still trucking along and he's super grateful,” she said.

Clinical champions within the practice

On practice-level infrastructure, Mobley described a model built around designated clinical champions. At her institution, 3 urologists share responsibility for all non-trial patients receiving the gemcitabine intravesical system, having collaboratively developed a stepwise protocol with 2 dedicated bladder cancer navigators. The framework gives navigators standing orders to initiate first-line management of irritative symptoms—anticholinergics, beta-3 agonists, phenazopyridine—with defined escalation pathways that bring the physician in when symptoms persist or intensify.

"We don't have a set rule that it absolutely goes A, B, C, D, E, but we have a framework and every patient is exposed to that same framework," Mobley said. The model also ensures consistency across coverage: if one physician is unavailable, a covering partner manages the patient the same way.

"We've all sat down and had that conversation and we're managing these patients in the same way," she said.